 |
104 Diseases |  |
139 Trials |
|
139 Trials |  |
6449 News |  |
| «12...79808182838485868788899091 |
- Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
New P2 trial: Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer (clinicaltrials.gov) - Nov 5, 2012
P2, N=56, Suspended, Sponsor: Manisha Shah
- | New P2 trial, Surgery: Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets (clinicaltrials.gov) - Nov 4, 2012
P2, N=39, Recruiting, Sponsor: University of California, San Francisco
- ||| Mekinist (trametinib) / Novartis, BeiGene
Enrollment open: A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 (clinicaltrials.gov) - Oct 3, 2012
P1, N=60, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting
- Biomarker, New P2 trial, Combination therapy, Surgery, Metastases: Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery (clinicaltrials.gov) - Oct 2, 2012
P2, N=20, Recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
- Enrollment open, Metastases: An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor (clinicaltrials.gov) - Sep 30, 2012
P2, N=45, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Enrollment change, Combination therapy: Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). (clinicaltrials.gov) - Sep 26, 2012
P3, N=852, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting N=1300 --> 852
- ||| Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis
Enrollment change, Combination therapy, Metastases: Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 (clinicaltrials.gov) - Aug 8, 2012
P2, N=430, Active, not recruiting, Sponsor: GlaxoSmithKline
N=1300 --> 852 N=280 --> 430
- ||| Mekinist (trametinib) / Novartis, BeiGene
New P1 trial: A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 (clinicaltrials.gov) - Aug 5, 2012
P1, N=60, Recruiting, Sponsor: GlaxoSmithKline
- ||||| Mekinist (trametinib) / Novartis, BeiGene
New P2 trial: Provide Continued Treatment with GSK1120212 to Subjects with Solid Tumors or Leukemia (EUDRACT) - Jul 30, 2012
P2, N=250, Ongoing, Sponsor: GlaxoSmithKline Research and Development Ltd
- ||| Mekinist (trametinib) / Novartis, BeiGene, uprosertib (LAE003) / Laekna Therap
Enrollment open, Combination therapy: Safety, Pharmacokinetics (PK) of AKT and MEK Combination (clinicaltrials.gov) - Jul 25, 2012
P1, N=240, Recruiting, Sponsor: GlaxoSmithKline
N=280 --> 430 Completed --> Recruiting
- Mekinist (trametinib) / Novartis, BeiGene
New P1 trial: A study to compare the tablet and oral solution formulations of GSK1120212 in cancer patients (EUDRACT) - Jul 24, 2012
P1, N=18, , Sponsor: GlaxoSmithKline Research and Development Ltd
- | Mekinist (trametinib) / Novartis, BeiGene
New P1 trial: Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation (clinicaltrials.gov) - Jul 19, 2012
P1, N=15, Completed, Sponsor: GlaxoSmithKline
- ||| Mekinist (trametinib) / Novartis, BeiGene
Enrollment closed, Metastases: An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 18, 2012
P2, N=120, Active, not recruiting, Sponsor: GlaxoSmithKline
Completed --> Recruiting Recruiting --> Active, not recruiting
- New P2 trial, Metastases: An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor (clinicaltrials.gov) - Jun 12, 2012
P2, N=45, Recruiting, Sponsor: M.D. Anderson Cancer Center
- |||||||||| Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
New P3 trial, Combination therapy, Monotherapy, Metastases: A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma (clinicaltrials.gov) - Apr 23, 2012
P3, N=423, Active, not recruiting, Sponsor: GlaxoSmithKline
- Mekinist (trametinib) / Novartis, BeiGene
Trial completion: Absolute Bioavialability of GSK1120212 (clinicaltrials.gov) - Apr 11, 2012
P1, N=4, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Recruiting --> Completed
- Mekinist (trametinib) / Novartis, BeiGene
Enrollment change: GSK1120212 Food-effect Study (clinicaltrials.gov) - Apr 2, 2012
P1, N=24, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed N=40 --> 24
- Mekinist (trametinib) / Novartis, BeiGene
Trial completion: Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212 (clinicaltrials.gov) - Apr 2, 2012
P1, N=2, Completed, Sponsor: GlaxoSmithKline
N=40 --> 24 Recruiting --> Completed
- | Mekinist (trametinib) / Novartis, BeiGene
Trial completion: GSK1120212 Food-effect Study (clinicaltrials.gov) - Apr 2, 2012
P1, N=24, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Recruiting --> Completed
- Mekinist (trametinib) / Novartis, BeiGene
New P2 trial: GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer (clinicaltrials.gov) - Mar 12, 2012
P2, N=20, Recruiting, Sponsor: Washington University School of Medicine
- ||| Mekinist (trametinib) / Novartis, BeiGene
Trial completion, Combination therapy: A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects (clinicaltrials.gov) - Dec 20, 2011
P1, N=90, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Active, not recruiting --> Completed
- ||| Mekinist (trametinib) / Novartis, BeiGene
Trial completion: Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma (clinicaltrials.gov) - Dec 20, 2011
P1, N=94, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Mekinist (trametinib) / Novartis, BeiGene, afuresertib (LAE002) / Laekna Therap
New P1/2 trial, Combination therapy: A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers (clinicaltrials.gov) - Nov 20, 2011
P1/2, N=20, Completed, Sponsor: GlaxoSmithKline
- ||| Mekinist (trametinib) / Novartis, BeiGene, pazopanib / Generic mfg.
Enrollment open, Combination therapy, Metastases: Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma (clinicaltrials.gov) - Nov 2, 2011
P1, N=111, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Mekinist (trametinib) / Novartis, BeiGene, pazopanib / Generic mfg.
New P1 trial, Combination therapy, Metastases: Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma (clinicaltrials.gov) - Sep 20, 2011
P1, N=111, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- | Mekinist (trametinib) / Novartis, BeiGene
New P1 trial: Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors (clinicaltrials.gov) - Sep 1, 2011
P1, N=32, Completed, Sponsor: GlaxoSmithKline
- Mekinist (trametinib) / Novartis, BeiGene
New P1 trial: Absolute Bioavialability of GSK1120212 (clinicaltrials.gov) - Aug 10, 2011
P1, N=4, Completed, Sponsor: GlaxoSmithKline